Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Capecitabine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | ADK | P55263 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | HBB | P68871 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.37 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.37 |
| ▸ | NT5E | P21589 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.35 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Capecitabine SCHEMBL12029777 | 1.00 | LMNA (1.00) | LMNAADKTSHRMAPTPMP22 | |
| Capecitabine SCHEMBL231286 | 1.00 | LMNA (1.00) | LMNAADKTSHRMAPTPMP22 | |
| Capecitabine SCHEMBL4939140 | 1.00 | LMNA (1.00) | LMNAADKTSHRMAPTPMP22 | |
| Capecitabine SCHEMBL2184820 | 1.00 | LMNA (1.00) | LMNAADKTSHRMAPTPMP22 | |
| Capecitabine SCHEMBL10013531 | 1.00 | LMNA (1.00) | LMNAADKTSHRMAPTPMP22 | |
| Capecitabine SCHEMBL21152105 | 1.00 | LMNA (1.00) | LMNAADKTSHRMAPTPMP22 | |
| Capecitabine SCHEMBL12302025 | 1.00 | LMNA (1.00) | LMNAADKTSHRMAPTPMP22 | |
| Capecitabine SCHEMBL2470888 | 1.00 | LMNA (1.00) | LMNAADKTSHRMAPTPMP22 | |
| Capecitabine SCHEMBL12948190 | 1.00 | LMNA (1.00) | LMNAADKTSHRMAPTPMP22 | |
| Capecitabine SCHEMBL12301996 | 1.00 | LMNA (1.00) | LMNAADKTSHRMAPTPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 546 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4534088-A1 | ARFOLITIXORIN FOR USE IN VITAMIN B6-ENHANCED, 5-FLUOROURACIL-BASED CHEMOTHERAPY OF CARCINOMAS | Isofol Medical AB (SE) | 2025-04-09 | — | — | EP | claimed |
| US-20240350467-A1 | [6R]-MTHF IN B6 ENHANCED 5-FU BASED CHEMOTHERAPY OF PANCREATIC CANCER | ISOFOL MEDICAL AB (SE) | 2024-10-24 | — | — | US | claimed |
| US-20240350495-A1 | [6R]-MTHF IN B6 ENHANCED 5-FU BASED CHEMOTHERAPY OF CARCINOMA | ISOFOL MEDICAL AB (SE) | 2024-10-24 | — | — | US | claimed |
| WO-2024218382-A1 | [6R]-MTHF IN B6 ENHANCED 5-FU BASED CHEMOTHERAPY OF PANCREATIC CANCER | ISOFOL MEDICAL AB (SE) | 2024-10-24 | — | — | WO | claimed |
| EP-4450071-A1 | [6R]-MTHF IN B6 ENHANCED 5-FU BASED CHEMOTHERAPY OF PANCREATIC CANCER | Isofol Medical AB (SE) | 2024-10-23 | — | — | EP | claimed |
| WO-2023046305-A1 | [6R]-MTHF IN 5-FU BASED CHEMOTHERAPY OF LEFT-SIDED COLORECTAL CANCER | ISOFOL MEDICAL AB (SE) | 2023-03-30 | — | — | WO | claimed |
| WO-2023046940-A1 | [6R]-MTHF IN 5-FU BASED CHEMOTHERAPY OF BRAF- OR KRAS-MUTATED COLORECTAL CANCER | ISOFOL MEDICAL AB (SE) | 2023-03-30 | — | — | WO | claimed |
| WO-2023046307-A1 | [6R]-MTHF IN 5-FU BASED CHEMOTHERAPY OF RIGHT-SIDED COLORECTAL CANCER | ISOFOL MEDICAL AB (SE) | 2023-03-30 | — | — | WO | claimed |
| WO-2023046304-A1 | [6R]-MTHF IN 5-FU BASED CHEMOTHERAPY OF BRAF- OR KRAS-MUTATED COLORECTAL CANCER | ISOFOL MEDICAL AB (SE) | 2023-03-30 | — | — | WO | claimed |
| US-20210401842-A1 | [6R]-MTHF - an efficient folate alternative in 5-fluorouracil based chemotherapy | ISOFOL MEDICAL AB (SE) | 2021-12-30 | — | — | US | claimed |
| EP-1551378-A2 | EPO D + 5-FU/GEMCITABINE | Kosan Biosciences, Inc. (US) | 2005-07-13 | — | — | EP | claimed |
| US-20040167222-A1 | Inhibition of melanogenesis and melanoma metastasis with p-aminobenzoic acid (PABA) | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-08-26 | — | — | US | claimed |
| US-20040167097-A1 | EPO D + 5-FU/gemcitabine | KOSAN BIOSCIENCES, INC. | 2004-08-26 | — | — | US | claimed |
| WO-2004032872-A2 | Epo D + 5-FU/GEMCITABINE | KOSAN BIOSCIENCES, INC. (US) | 2004-04-22 | — | — | WO | claimed |
| EP-1392296-A1 | THIAZOLIDINEDIONES ALONE OR IN CONBINATION WITH OTHER THERAPEUTIC AGENTS FOR INHIBITING OR REDUCING TUMOUR GROWTH | F. HOFFMANN-LA ROCHE AG (CH) | 2004-03-03 | — | — | EP | claimed |
| WO-2002080913-A1 | THIAZOLIDINEDIONES ALONE OR IN COMBINATION WITH OTHER THERAPEUTIC AGENTS FOR INHIBITING OR REDUCING TUMOUR GROWTH | F. HOFFMANN-LA ROCHE AG (CH) | 2002-10-17 | — | — | WO | claimed |
| EP-1060183-A1 | 5'-DEOXYCYTIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-12-20 | — | — | EP | claimed |
| WO-1999040099-A1 | 5'-DEOXYCYTIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1999-08-12 | — | — | WO | claimed |
| EP-0602454-B1 | N-Oxycarbonyl substituted 5'-deoxy-5-fluorocytidines | HOFFMANN LA ROCHE (CH) | 1996-04-24 | — | — | EP | claimed |
| EP-0602454-A1 | N-Oxycarbonyl substituted 5'-deoxy-5-fluorocytidines | F. HOFFMANN-LA ROCHE AG (CH) | 1994-06-22 | — | — | EP | claimed |